spike
protein
sar
coronaviru
sarscov
respons
viral
bind
molecul
receptorbind
motif
srbm
locat
residu
fold
antiparallel
previous
demonstr
fragment
protein
predominantli
recogn
convalesc
sera
sar
patient
ntermin
residu
fragment
cover
entir
strand
srbm
present
studi
demonstr
patient
sera
predominantli
recogn
linear
epitop
outsid
fragment
mous
antisera
induc
immun
balbc
mice
recombin
mainli
recogn
strandcontain
region
unlik
patient
sera
howev
mous
antisera
unabl
inhibit
infect
proteinexpress
sarscov
pseudoviru
fusion
protein
green
fluoresc
protein
gfp
abl
stain
vero
cell
delet
fragment
render
fusion
product
unabl
similarli
recombin
abl
block
infect
vero
cell
sarscov
pseudoviru
coprecipit
experi
confirm
abl
specif
bind
molecul
lysat
vero
cell
howev
abil
either
alon
fusion
gfp
bind
significantli
poorer
compar
data
suggest
possibl
although
strand
alon
abl
bind
rel
high
affin
residu
outsid
srbm
could
also
assist
receptor
bind
sarscov
protein
sarsassoci
coronaviru
sarscov
positivestrand
rna
viru
coronavirida
famili
caus
agent
sever
acut
respiratori
syndrom
sar
infect
peopl
around
world
peiri
et
al
rota
et
al
genom
sarscov
encod
sever
structur
protein
includ
spike
glycoprotein
nucleocapsid
protein
membran
protein
envelop
protein
marra
et
al
protein
sarscov
consist
amino
acid
residu
approxim
homolog
human
cov
ho
et
al
spiga
et
al
mediat
viral
bind
angiotensinconvert
cell
surfac
zinc
peptidas
protein
receptorbind
domain
srbd
map
fragment
residu
li
et
al
recent
solv
crystal
structur
srbd
complex
resolut
result
demonstr
srbd
contain
subdomain
core
residu
extend
loop
residu
latter
refer
protein
receptor
bind
motif
srbm
form
antiparallel
fold
gentli
concav
surfac
make
contact
molecul
interestingli
amino
acid
residu
srbm
direct
contact
strand
residu
suggest
possibl
fragment
alon
might
abl
bind
consider
affin
receptor
bind
site
sarscov
srbd
like
target
neutral
ab
viru
sever
group
map
number
b
cell
epitop
around
srbd
region
hu
et
al
hua
et
al
hua
et
al
lu
et
al
wang
et
al
although
exact
locat
conform
structur
epitop
remain
clarifi
previou
result
demonstr
sar
patient
mount
earli
strong
humor
respons
fragment
protein
zhao
et
al
zhao
et
al
contain
strand
srbm
herein
analyz
receptor
bind
abil
also
antigen
term
recognit
ab
express
purif
recombin
truncat
polypeptid
fusion
product
gfp
prepar
recombin
previous
describ
zhao
et
al
zhao
et
al
dna
encod
truncat
fragment
cover
sequenc
name
si
sii
siii
siv
sv
amplifi
pcr
use
vector
encod
sarscov
templat
result
product
insert
prokaryot
express
vector
dna
encod
gfp
insert
downstream
protein
gene
prepar
gfp
fusion
protein
fig
glycineand
serinerich
linker
variou
length
wide
use
protein
engin
sinc
linker
may
offer
littl
structur
hindranc
fold
protein
construct
nardella
et
al
linker
sequenc
gsggsg
therefor
introduc
fragment
gfp
recombin
product
express
e
coli
purifi
homogen
use
ni
column
examin
sdspage
electrophoresi
fig
previou
studi
demonstr
presenc
b
cell
epitop
srbd
screen
synthet
recombin
polypeptid
cover
sequenc
elisa
wb
assay
chen
et
al
zhang
et
al
map
b
cell
epitop
region
set
convalesc
patient
sera
test
posit
sarscovbas
elisa
previous
describ
zhao
et
al
screen
wb
experi
recombin
si
sii
siii
siv
sv
illustr
fig
sii
siv
strongli
recogn
patient
sera
none
overlap
construct
produc
detect
signal
result
impli
fragment
residu
repres
either
linear
b
cell
epitop
part
conform
b
cell
epitop
predominantli
recogn
human
ab
produc
follow
infect
sarscov
balbc
mice
sc
immun
recombin
emulsifi
cfa
subsequ
test
serum
ab
immun
ag
also
truncat
polypeptid
wb
assay
contrari
obtain
patient
sera
mous
antiserum
strongli
recogn
si
weakli
recogn
siii
siv
recogn
sv
fig
comparison
neutral
abil
patient
sera
mous
antiserum
cotransfect
cell
sarscovsproteinexpress
vector
defect
luciferas
prepar
sprotein
express
pseudoviru
pseudoviru
thu
obtain
abl
infect
vero
cell
vitro
evidenc
approxim
fold
increas
luciferas
activ
infect
cell
fig
system
employ
compar
neutral
abil
patient
sera
mous
antiserum
shown
fig
convalesc
patient
sera
mous
antiserum
abl
specif
neutral
sproteinexpress
pseudoviru
infect
vero
cell
impli
ab
specif
linear
epitop
strand
necessarili
associ
neutral
abil
human
mous
sera
test
herein
unabl
neutral
infect
vsvg
pseudoviru
fig
confirm
specif
system
assess
receptor
bind
abil
fragment
vero
cell
treat
recombin
follow
either
convalesc
patient
serum
control
serum
sampl
hd
mous
antiserum
ma
normal
mous
serum
nm
srbdfc
fusion
protein
srbd
domain
residu
fc
fragment
human
shown
abl
bind
receptor
high
affin
kuba
et
al
control
srbdfc
human
iggfc
use
treat
vero
also
cell
wash
cell
subsequ
treat
fitcconjug
secondari
ab
fac
analysi
illustr
fig
b
vero
cell
specif
recogn
patient
serum
mous
antiserum
indic
specif
bind
recombin
cell
surfac
locat
site
receptor
bind
within
construct
next
employ
fusion
protein
direct
stain
vero
cell
expect
abl
label
vero
cell
delet
sequenc
complet
abolish
abil
fig
e
noteworthi
intens
vero
cell
stain
fig
fig
approxim
srbdfc
fig
fluoresc
intens
cell
stain
srbd
experi
shown
fig
vero
cell
treat
recombin
wash
lyse
use
lysi
buffer
lysat
treat
sequenti
serum
protein
agagaros
precipit
complex
result
precipit
run
sdspage
gel
assay
wb
ab
first
ab
fig
illustr
materi
contain
molecul
kda
band
specif
recogn
goat
antihuman
ab
parallel
experi
cell
lysat
precipit
use
goat
antihuman
polyclon
ab
precipit
analyz
wb
use
serum
first
ab
kda
protein
band
correspond
size
polypeptid
clearli
visual
fig
identif
neutral
epitop
protein
great
interest
vaccin
design
also
understand
antisarscov
humor
immun
patient
demonstr
srbd
residu
contain
immunodomin
b
cell
epitop
recogn
neutral
ab
et
al
sui
et
al
presum
neutral
epitop
locat
within
srbm
region
residu
form
direct
contact
howev
far
confirm
experiment
data
wb
assay
strand
ie
si
recogn
convalesc
patient
sera
fig
although
strand
predominantli
recogn
antisera
mice
immun
construct
fig
ab
show
neutral
abil
sarscov
pseudoviru
infect
fig
immun
mice
srbdfc
adopt
natur
fold
srbd
kuba
et
al
et
al
gener
panel
mab
two
specif
linear
epitop
residu
neither
mab
abl
neutral
viral
infect
agreement
data
shown
fig
indic
lack
neutral
abil
mous
ab
specif
linear
sequenc
strand
like
genuin
phenomenon
rather
result
improp
present
context
peptid
also
emphas
howev
result
exclud
possibl
strand
whole
srbm
fold
form
strand
togeth
contain
conformationdepend
b
cell
epitop
predominantli
recogn
neutral
ab
wb
assay
reduc
denatur
natur
sdspage
would
allow
protein
ag
recogn
linear
form
wb
result
also
show
fragment
near
srbm
residu
specif
recogn
patient
sera
test
fig
whether
bind
human
ab
epitop
contribut
neutral
still
unclear
although
correl
specif
mostli
target
epitop
neutral
abil
convalesc
sera
provid
circumstanti
evid
notion
jc
zhao
unpublish
observ
furthermor
data
report
li
et
al
et
al
suggest
ab
bind
region
near
srbm
fold
may
caus
conform
chang
receptor
bind
site
result
inhibit
rbd
bind
although
construct
contain
half
srbm
fold
strand
nonetheless
abl
bind
rel
high
affin
determin
cellular
stain
pseudoviru
inhibit
assay
coprecipit
experi
fig
also
support
hu
et
al
document
recombin
block
bind
srbd
hu
et
al
addit
comput
model
result
show
strand
contribut
significantli
term
contact
area
vs
well
bind
energi
vs
kjmol
interact
fig
unexpect
find
studi
construct
either
alon
fusion
gfp
rel
poor
bind
compar
determin
vero
cell
stain
fig
sarscov
pseudoviru
inhibit
fig
experi
sever
possibl
explan
phenomenon
case
gfpfusion
protein
employ
possibl
fig
stain
vero
cell
gfp
fusion
protein
indirect
stain
b
vero
cell
treat
pb
h
follow
convalesc
patient
serum
mous
antiserum
ma
serum
sampl
healthi
blood
donor
hd
normal
mous
serum
nm
fitcconjug
goat
antihuman
goatantimous
igg
ab
employ
secondari
ab
control
vero
cell
cell
treat
srbdfc
human
igg
h
follow
fitcconjug
goat
antihuman
igg
c
f
direct
stain
vero
e
cell
treat
gfp
min
wash
cell
subject
flow
cytometr
analysi
site
kda
peptid
could
physic
block
kda
gfp
block
effect
significantli
lessen
construct
bind
effici
perhap
buffer
effect
residu
ie
gfp
addit
start
molecul
middl
srbm
fold
might
pronetomisfold
thirdli
sequenc
adjac
srbm
may
also
assist
receptor
bind
srbm
yet
unknown
mechan
virtu
format
inter
intramolecular
disulfid
bond
bind
polypeptid
could
stabil
enhanc
well
xiao
et
al
found
dimer
state
portion
protein
could
contribut
increas
overal
affin
may
enhanc
fusion
effici
hypothesi
may
help
explain
fact
ab
region
adjac
srbm
exhibit
neutral
potenti
high
fidel
taq
dna
polymeras
purchas
takara
biotech
co
ltd
shiga
japan
restrict
enzym
fig
interact
strand
srbm
crystal
structur
rbd
complex
human
receptor
report
li
cowork
detail
bind
interfac
srbm
molecul
calcul
result
contact
area
bind
energi
shown
panel
b
c
respect
proteinbind
area
molecul
purpl
color
green
strand
gold
bind
energi
energi
requir
disassembl
complex
separ
part
figur
prepar
use
pymol
contact
area
bind
energi
calcul
spdbv
pdb
file
access
number
fig
coprecipit
recombin
lysat
vero
cell
vero
cell
sequenti
treat
goat
antihuman
ab
goat
igg
fitcconjug
rabbit
antigoat
igg
stain
cell
subject
flow
cytometr
analysi
determin
express
cell
surfac
coprecipit
experi
b
vero
cell
treat
without
recombin
h
wash
cell
lyse
use
lysi
buffer
lysat
treat
serum
follow
proteinagagaros
precipit
precipit
materi
run
sdspage
gel
protein
band
transfer
nitrocellulos
membran
wb
assay
use
goat
antihuman
ab
first
ab
detect
ab
hrplabel
rabbit
antigoat
igg
parallel
experi
c
lysat
untreat
vero
cell
precipit
use
goat
antihuman
ab
proteinagagaros
precipit
assay
wb
use
serum
first
ab
hrplabel
goat
antihuman
igg
detect
ab
ligas
invitrogen
california
usa
kit
dna
extract
purif
qiagen
hilden
germani
e
coli
strain
stratagen
la
jolla
california
usa
ninitrilotriacet
acid
ninta
resin
novagen
darmstadt
germani
protein
agagaros
immunoprecipit
suppli
santa
cruz
biotechnolog
inc
california
usa
cell
transfect
reagent
vigor
biotech
co
beij
china
luciferas
assay
reagent
suppli
promega
madison
usa
goat
antihuman
ectodomain
polyclon
ab
purchas
r
system
minneapoli
mn
usa
fitcconjug
rabbit
antigoat
goat
antihuman
goat
antimous
igg
horseradish
peroxidas
hrp
label
goat
antihuman
goat
antimous
igg
obtain
zhongshan
biotech
co
beij
china
vero
cell
cell
obtain
atcc
propag
dmem
supplement
fetal
bovin
serum
hyclon
utah
usa
serum
sampl
use
studi
convalesc
sar
patient
collect
juli
august
beij
red
cross
center
blood
sampl
process
within
h
collect
addit
control
serum
sampl
hd
prepar
mix
sera
randomli
select
healthi
blood
donor
express
vector
contain
gene
previous
describ
zhao
et
al
zhao
et
al
dna
encod
truncat
fragment
pcr
amplifi
use
templat
vector
contain
gene
green
fluoresc
protein
gfp
gift
dr
l
barber
imperi
colleg
school
scienc
technolog
medicin
london
prepar
gfp
fusion
protein
linker
sequenc
glyserglyglyserglys
ad
protein
fragment
gfp
use
sequenc
overlap
extens
pcr
method
dna
sequenc
encod
protein
fragment
gfp
fusion
protein
insert
express
vector
recombin
product
express
e
coli
purifi
use
ninta
resin
follow
manufactur
instruct
prepar
srbdfc
recombin
fusion
protein
srbd
residu
fc
portion
human
express
cho
cell
purifi
chromatographi
describ
elsewher
kuba
et
al
femal
balbc
mice
week
age
obtain
institut
genet
development
biolog
chines
academi
scienc
beij
china
immun
sc
recombin
pb
emulsifi
complet
freund
adjuv
cfa
sigma
usa
base
tail
booster
immun
given
day
emulsifi
incomplet
freund
adjuv
ifa
mice
bled
sera
week
third
immun
serum
sampl
kept
use
procedur
ipwestern
blot
assay
accord
li
et
al
briefli
vero
cell
treat
without
recombin
h
cell
wash
time
lyse
lysi
buffer
contain
proteas
inhibitor
pepstinin
leupeptin
aproptinin
sigma
remov
cell
debri
centrifug
lysat
allow
mix
either
serum
dilut
goatantihuman
ab
final
concentr
overnight
sera
healthi
subject
hd
goat
igg
also
includ
control
protein
agagaros
ad
incub
h
follow
wash
bound
protein
elut
laemmli
sampl
buffer
min
separ
sdspage
gel
protein
band
transfer
onto
nitrocellulos
membran
wb
assay
use
goat
antihuman
ab
serum
first
ab
nitrocellulos
membran
recombin
protein
transfer
sdspage
gel
block
room
temperatur
h
block
solut
nonfat
dri
milk
incub
h
room
temperatur
convalesc
sera
sar
patient
dilut
antisera
mice
immun
dilut
wash
trisbuff
salin
tb
contain
tween
tbst
membran
incub
hrplabel
goat
antihuman
antimous
igg
tetrahydrochlorid
dab
sigma
use
visual
reaction
indirect
stain
experi
vero
cell
treat
recombin
h
wash
cell
incub
min
presenc
patient
sera
dilut
mous
antiserum
dilut
serum
sampl
healthi
blood
donor
naiv
balbc
mice
includ
control
recombin
srbdfc
human
iggfc
also
employ
treat
vero
cell
h
control
wash
cell
incub
fitcconjug
goat
antihuman
goatantimous
igg
min
analyz
facscan
bd
direct
stain
experi
vero
cell
treat
gfp
gfp
fusion
protein
min
follow
flow
cytometr
analysi
use
facscan
machin
gfp
singl
excit
peak
nm
emiss
peak
nm
adapt
common
fluorescein
isothiocyan
fitc
bandpass
fac
gerd
kaether
prepar
sarscovsproteinexpress
pseudoviru
accord
method
nie
et
al
briefli
cell
seed
cm
diamet
tissu
cultur
dish
one
day
earlier
cotransfect
defect
genom
e
plasmid
pvsvg
encod
vesicular
stomat
viru
vsv
g
protein
plasmid
pcmv
encod
protein
sarscov
use
vigor
transfect
reagent
vigor
biotech
co
beij
china
defect
hivgenom
contain
gene
luciferas
use
report
success
infect
pseudoviru
cultur
medium
replac
fresh
medium
h
posttransfect
cell
cultur
addit
h
cultur
supernat
contain
vsvgpseudoviru
sarsspseudoviru
harvest
filter
poses
filter
follow
centrifug
rpm
h
use
beckman
ultra
centrifug
beckman
coulter
harbor
boulevard
usa
pseudovir
pellet
resuspend
pb
titrat
aliquot
store
use
neutral
block
assay
use
sarscov
pseudoviru
system
sarscov
pseudoviru
vsvg
pseudoviru
infect
cell
neutral
accord
zhang
et
al
briefli
vero
cell
seed
plate
densiti
cellswel
cultur
overnight
serial
dilut
serum
sampl
recombin
protein
mix
pseudoviru
prepar
min
mixtur
ad
well
monolay
vero
cell
incub
h
mixtur
well
replac
fresh
medium
cell
cultur
addit
h
wash
cell
lyse
use
luciferas
assay
reagent
promega
ua
luciferas
activ
cell
lysat
determin
use
verita
micropl
luminomet
turner
biosystem
luciferas
activ
refer
group
vero
cell
treat
pseudoviru
alon
taken
infect
cell
treat
pseudoviru
includ
specif
control
luciferas
activ
read
least
log
lower
refer
group
experi
luciferas
activ
experiment
group
vero
cell
treat
pseudoviru
prepar
presenc
serum
ab
block
reagent
compar
refer
group
result
express
percent
infect
calcul
follow
luciferas
activ
experiment
group
luciferas
activ
refer
group
experi
describ
repeat
least
time
comparison
data
perform
use
student
test
signific
defin
p
valu
